Sodium Chloride Cotransporter Regulation by WNK Kinase

WNK 激酶调节氯化钠协同转运蛋白

基本信息

  • 批准号:
    6983057
  • 负责人:
  • 金额:
    $ 10.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-30 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): WNKs (with no lysine (K)) are a newly described novel subfamily of serine/threonine kinases implicated in controlling the ionic permeability of epithelia. Mutations in WNK1 and WNK4 kinases are found to cause pseudohypoaldosteronism type II (PHA II), also referred to as Gordon syndrome. PHA II is a rare autosomal dominant disorder featuring hypertension, hyperkalemia and metabolic acidosis. Its clinical features are reversed by a thiazide diuretic, a sodium chloride cotransporter (NCC) inhibitor. Immunofluorescent studies and Northern blot analysis demonstrated that both WNK1 and WNK4 are present in a variety of polarized epithelia involved in chloride ion transport, such as kidney, clonic crypts, sweat ducts, pancreatic ducts, biliary ducts, epididymis and the ependyma of the brain. Mutations in WNK kinases resulting in PHA II suggest that WNK kinase is involved in the regulation of sodium chloride handling by the distal nephron. Recent studies have shown an inhibitory effect of WNK4 on NCC activity and surface expression of NCC in Xenopus oocytes, further demonstrating that WNK4 kinase regulates NCC function through direct or indirect mechanisms. This research proposal is to examine the role of WNK4 kinase in NCC regulation in the renal tubular cells. The hypothesis to be tested is that inappropriate targeting and/or function of the WNK4 kinase will affect NCC regulation directly by altering the NCC processing and/or indirectly by altering the phosphorylation of NCC in mammalian cells. This hypothesis is supported by strong preliminary data that surface expression of NCC is significantly reduced by WNK4. In contrast, NCC surface expression is unaffected by WNK4 mutants in African green monkey kidney (Cos-7) cells. Further investigating the regulation of NCC by WNK4 will provide important information to understanding the physiological role of WNK4 kinase and help to identify the underlying mechanisms of PHA II that are crucial in better understanding the pathogenesis of essential hypertension.
描述(由申请人提供): WNK(不含赖氨酸(K))是一种新发现的丝氨酸/苏氨酸激酶亚家族,参与控制上皮细胞的离子渗透性。发现WNK 1和WNK 4激酶的突变可引起假性醛固酮减少症II型(PHA II),也称为戈登综合征。PHA II是一种罕见的常染色体显性遗传疾病,以高血压、高钾血症和代谢性酸中毒为特征。其临床特征可通过噻嗪类利尿剂(一种氯化钠协同转运蛋白(NCC)抑制剂)逆转。免疫荧光研究和北方印迹分析表明,WNK 1和WNK 4都存在于参与氯离子转运的各种极化上皮细胞中,如肾脏、阵挛性隐窝、汗管、胰管、胆管、附睾和大脑的室管膜。导致PHA II的WNK激酶突变表明WNK激酶参与远端肾单位对氯化钠处理的调节。最近的研究表明,WNK 4对非洲爪蟾卵母细胞中NCC活性和NCC表面表达的抑制作用,进一步证明WNK 4激酶通过直接或间接机制调节NCC功能。本研究拟探讨WNK 4激酶在肾小管细胞NCC调控中的作用。待检验的假设是WNK 4激酶的不适当靶向和/或功能将通过改变NCC加工直接影响NCC调节和/或通过改变哺乳动物细胞中NCC的磷酸化间接影响NCC调节。这一假设得到了强有力的初步数据的支持,即NCC的表面表达被WNK 4显著降低。相比之下,NCC表面表达不受非洲绿色猴肾(Cos-7)细胞中WNK 4突变体的影响。进一步研究WNK 4对NCC的调控将为理解WNK 4激酶的生理作用提供重要信息,并有助于确定PHA II的潜在机制,这些机制对于更好地理解原发性高血压的发病机制至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HUI CAI其他文献

HUI CAI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HUI CAI', 18)}}的其他基金

Regulation of Renal Maxi K Channel by WNK Kinase
WNK 激酶对肾 Maxi K 通道的调节
  • 批准号:
    8245525
  • 财政年份:
    2012
  • 资助金额:
    $ 10.85万
  • 项目类别:
Regulation of Renal Maxi K Channel by WNK Kinase
WNK 激酶对肾 Maxi K 通道的调节
  • 批准号:
    8598014
  • 财政年份:
    2012
  • 资助金额:
    $ 10.85万
  • 项目类别:
Role of BK Channel in Chronic Kidney Disease
BK 通道在慢性肾脏病中的作用
  • 批准号:
    10620115
  • 财政年份:
    2012
  • 资助金额:
    $ 10.85万
  • 项目类别:
Role of BK Channel in Chronic Kidney Disease
BK 通道在慢性肾脏病中的作用
  • 批准号:
    10367944
  • 财政年份:
    2012
  • 资助金额:
    $ 10.85万
  • 项目类别:
Regulation of Renal Maxi K Channel by WNK Kinase
WNK 激酶对肾 Maxi K 通道的调节
  • 批准号:
    8413384
  • 财政年份:
    2012
  • 资助金额:
    $ 10.85万
  • 项目类别:
Regulation of Renal BK Channel by WNK Kinase and its Interacting Proteins
WNK 激酶及其相互作用蛋白对肾 BK 通道的调节
  • 批准号:
    9032313
  • 财政年份:
    2011
  • 资助金额:
    $ 10.85万
  • 项目类别:
Regulation of Renal BK Channel by WNK Kinase and its Interacting Proteins
WNK 激酶及其相互作用蛋白对肾 BK 通道的调节
  • 批准号:
    9217384
  • 财政年份:
    2011
  • 资助金额:
    $ 10.85万
  • 项目类别:
Sodium Chloride Cotransporter Regulation by WNK Kinase
WNK 激酶调节氯化钠协同转运蛋白
  • 批准号:
    7996213
  • 财政年份:
    2010
  • 资助金额:
    $ 10.85万
  • 项目类别:
Sodium Chloride Cotransporter Regulation by WNK Kinase
WNK 激酶调节氯化钠协同转运蛋白
  • 批准号:
    7459083
  • 财政年份:
    2005
  • 资助金额:
    $ 10.85万
  • 项目类别:
Sodium Chloride Cotransporter Regulation by WNK Kinase
WNK 激酶调节氯化钠协同转运蛋白
  • 批准号:
    7409935
  • 财政年份:
    2005
  • 资助金额:
    $ 10.85万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 10.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 10.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 10.85万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 10.85万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 10.85万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 10.85万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 10.85万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 10.85万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 10.85万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 10.85万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了